FDA-Approved Gene Therapy Reverses Blindness in Children & Adults

Medical Breakthroughs from Penn Medicine

Contenido proporcionado por ReachMD. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente ReachMD o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

6+ y ago

MP3•Episodio en casa

Fetch error

Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on January 10, 2024 12:11 (10M ago)

What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.

Host: Jennifer Caudle, DO
Guest: Jean Bennett, MD, PhD
Guest: Albert Maguire, MD
Power couple Drs. Jean Bennett and Albert Maguire discuss how their new therapy for the RPE65 gene, which causes retinal blindness, was recently approved by the FDA to become the first gene therapy treatment for a genetic disease in the United States and the first worldwide treatment for inherited blindness. Not only do they delve into the mechanics of the corrected gene injection, but they also explain what this milestone means for patient eligibility and how their marriage has played a role in the success of their research partnership. Dr. Jean Bennett is the F.M. Kirby Professor of Ophthalmology at the Perelman School of Medicine at the University of Pennsylvania, and Dr. Albert Maguire is a Professor of Ophthalmology at the Hospital of the University of Pennsylvania and Attending Physician in the Division of Pediatric Ophthalmology at Children’s Hospital of Philadelphia.

114 episodios

#Science #Medicine #Breast Cancer #ReachMD #Health and Well-Being